EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
08/11/2026
Back to search
Official data from USPTO
TRANSCON
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
TRANSCON
ST13
US500000079221044Class
5, 42, 45
Filing
79221044
Registration
5881763
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
08/11/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 42, 45
Filing date
07/17/2017
Registration date
10/15/2019
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/15/2019
Last transaction
08/11/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
Hellerup, DK
Examiner
PAPALE, LISA ANNE
Current location
Historical data usage
Holders and representatives
Holders
Ascendis Pharma A/S
Ascendis Pharma A/S
Representatives
Shannon Marie McKeon Dykema Gossett PLLC
Technical classification
Nice Classes
Class 5Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary preparationsa drug delivery system in the form of polymer based prodrug formulations which allow for the controlled or continuous release of a wide variety of therapeutic agents for the treatment of mental illness and physical illness in the nature of disorder of the endocrine systemgrowth hormone deficiencyhypoparathyroidismachondroplasiadiabetesfibroblast growth factor receptor (FGFR)-related skeletal disordersoncologyophthalmologyinfectious diseaseenzyme replacement therapyanti-inflammatory diseasepainrespiratory system disorderautoimmune disordersvaccinesnon-alcoholic steatohepatitisbrain diseasesbone diseasesCNS diseasesmyopathiesobesitywound healing; sanitary preparations for medical purposes; dietetic substances adapted for medical use; disinfectants; fungicides; herbicides
Class 42
Scientific research within the medicalpharmaceutical and bacteriological area and consultancy and information relating thereto; conducting of tests regarding medical applications in the nature of providing medical testing services in the field of sustained release of pharmaceutical and veterinary drugs; designing and development of medical equipment; designing pharmaceutical and medical preparations in the nature of pharmaceutical drug development services; development of pharmaceutical formulations; design and development of pharmaceutical granulation technology and pharmaceutical tablet technology and consultancy and information relating thereto
Class 45
Licensing of industrial property rights; legal services
Publications
History of USPTO decisions and trademark events.
50 publications found
PR71
POST REGISTRATION ACTION MAILED - SEC.71
03/10/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
03/08/2026
ES71
TEAS SECTION 71 RECEIVED
10/31/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/15/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/10/2024
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/24/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/28/2021
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/21/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/04/2020
FIMP
FINAL DISPOSITION PROCESSED
02/03/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/15/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
10/15/2019
GPNX
NOTIFICATION PROCESSED BY IB
08/23/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/30/2019
PUBO
PUBLISHED FOR OPPOSITION
07/30/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/10/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/10/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/21/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
06/20/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/20/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
06/20/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/20/2019
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/03/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/17/2019
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/17/2019
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
01/11/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
07/11/2018
GNSL
LETTER OF SUSPENSION E-MAILED
07/11/2018
CNSL
SUSPENSION LETTER WRITTEN
07/11/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
07/11/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/11/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
07/11/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/11/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/21/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/21/2018
ALIE
ASSIGNED TO LIE
06/20/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/06/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/23/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/23/2018
RFNT
REFUSAL PROCESSED BY IB
12/29/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/08/2017
RFRR
REFUSAL PROCESSED BY MPU
12/08/2017
MAFR
APPLICATION FILING RECEIPT MAILED
11/28/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/26/2017
CNRT
NON-FINAL ACTION WRITTEN
11/25/2017
DOCK
ASSIGNED TO EXAMINER
11/22/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/22/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/16/2017
Continuous trademark protection
Get notified about every new filing that threatens TRANSCON or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.